Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in adults with sickle cell disease
NL-OMON54689Phase 2Recruiting
- Sponsor
- Julius Clinical
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitapivat in sickle cell disease (SCD) and sickle cell anemia (SCA), sponsored by Julius Clinical. Primary endpoints: Maximum efficacy on point of sickling during dose finding, Efficacy on point of sickling during fixed dose extension and 1 more. Started Sep 2020; status: recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)sickle cell anemia (SCA)
Beyond the preview
Go deeper on NL-OMON54689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54689.